{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06334133",
            "orgStudyIdInfo": {
                "id": "TTP399-302"
            },
            "organization": {
                "fullName": "vTv Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes",
            "officialTitle": "Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes: A 52-Week Double-Blind, Randomized, Placebo-Controlled Phase 3 Study",
            "acronym": "CATT1",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "cadisegliatin-as-adjunctive-therapy-in-type-diabetes"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-13",
            "studyFirstSubmitQcDate": "2024-03-20",
            "studyFirstPostDateStruct": {
                "date": "2024-03-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-02",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-03",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "vTv Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 3 trial of cadisegliatin in participants with Type 1 Diabetes Mellitus.",
            "detailedDescription": "Study TTP399-302 is a 52-week, Phase 3 trial designed to measure the relative efficacy of treatment with cadisegliatin to reduce the incidence of Level 2 or Level 3 hypoglycemia in participants with Type 1 Diabetes Mellitus compared to placebo over 26 weeks of continuous therapy."
        },
        "conditionsModule": {
            "conditions": [
                "Diabetes Mellitus, Type 1"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg QD",
                    "type": "EXPERIMENTAL",
                    "description": "The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.",
                    "interventionNames": [
                        "Drug: Cadisegliatin 800 mg QD"
                    ]
                },
                {
                    "label": "Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg BID",
                    "type": "EXPERIMENTAL",
                    "description": "The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.",
                    "interventionNames": [
                        "Drug: Cadisegliatin 800 mg BID"
                    ]
                },
                {
                    "label": "Placebo: 52 Week Double Blind Treatment Period",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "The main study uses a randomized, double-blind, placebo-controlled design with parallel assignment among 3 treatment arms. The trial begins with a screening period of up to 14 days, followed by a 28-day device training and insulin adjustment period leading into a 28-day baseline period before entering the 52-week treatment period.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Cadisegliatin 800 mg QD",
                    "description": "Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.",
                    "armGroupLabels": [
                        "Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg QD"
                    ],
                    "otherNames": [
                        "TTP399"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cadisegliatin 800 mg BID",
                    "description": "Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.",
                    "armGroupLabels": [
                        "Cadisegliatin: 52 Week Double Blind Treatment Period - 800 mg BID"
                    ],
                    "otherNames": [
                        "TTP399"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Placebo",
                    "armGroupLabels": [
                        "Placebo: 52 Week Double Blind Treatment Period"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in incidence of Level 2 or Level 3 hypoglycemia",
                    "description": "Number of events of Level 2 or Level 3 hypoglycemia in participants on cadisegliatin vs placebo.",
                    "timeFrame": "26 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To assess the change in HbA1c",
                    "description": "Change from baseline in HbA1c in participants on cadisegliatin vs placebo.",
                    "timeFrame": "26 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on CGM-based metrics for glycemic control",
                    "description": "To evaluate the change from baseline for time in, above or below target range of participants on cadisegliatin vs placebo",
                    "timeFrame": "26 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on the incidence of diabetic ketoacidosis",
                    "description": "Number of events of diabetic ketoacidosis participants on cadisegliatin vs placebo",
                    "timeFrame": "26 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on insulin dosing",
                    "description": "Change from baseline in basal, bolus and total insulin dosing",
                    "timeFrame": "26 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on body weight",
                    "description": "Change from baseline in mean body weight",
                    "timeFrame": "26 weeks"
                },
                {
                    "measure": "To assess the incidence of adverse events",
                    "description": "Evaluation and comparison of the number of adverse events with cadisegliatin vs placebo during the study",
                    "timeFrame": "26 weeks"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Change in incidence of Level 2 or Level 3 hypoglycemia",
                    "description": "Number of events of Level 2 or Level 3 hypoglycemia in participants on cadisegliatin vs placebo.",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To assess the change in HbA1c",
                    "description": "Change from baseline in HbA1c in participants on cadisegliatin vs placebo",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on CGM-based metrics for glycemic control",
                    "description": "To evaluate the change from baseline for time in, above or below target range of participants on cadisegliatin vs placebo",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To assess the incidence of adverse events",
                    "description": "Evaluation and comparison of the number of adverse events with cadisegliatin vs placebo during the study",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on the incidence of diabetic ketoacidosis",
                    "description": "Percentage of participants with incidence of diabetic ketoacidosis on cadisegliatin vs placebo",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on insulin dosing",
                    "description": "Change from baseline in basal, bolus and total insulin dosing",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "To assess the effects of treatment on body weight",
                    "description": "Change from baseline in mean body weight",
                    "timeFrame": "52 weeks"
                },
                {
                    "measure": "High sensitivity C-reactive protein",
                    "description": "Change from baseline of biomarkers",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "N-terminal pro brain [or B-type] natriuretic peptide",
                    "description": "Change from baseline of biomarkers",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "Urinary albumin excretion ratio",
                    "description": "Change from baseline of biomarkers",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "Estimated glomerular filtration rate",
                    "description": "Change from baseline of biomarkers",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "Gold hypoglycemia awareness score",
                    "description": "Change from baseline in patient reported outcomes scores to assess the burden of hypoglycemia. Scale from 1 (always aware) to 7 (never aware).",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "Item 7 of Clarke hypoglycemia awareness scale",
                    "description": "Change from baseline in patient reported outcomes scores to assess the burden of hypoglycemia. Scale from less than 40 mg/dL to 79mg/dL.",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "Snyder's 1-item quality of sleep questionnaire",
                    "description": "Change from baseline in patient reported outcomes scores to assess the burden of hypoglycemia. Scale from 0 (terrible) to 10 (excellent).",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "World Health Organization-5 Well-Being Index",
                    "description": "Change from baseline in patient reported outcomes scores to assess the burden of hypoglycemia. Ranges from not confident to very confident.",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "8-item Diabetes Distress Scale (participant and partner or family member)",
                    "description": "Change from baseline in PRO scores to assess the burden of hypoglycemia",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "Hypoglycemia Confidence Scale for participant and partner or family member",
                    "description": "Change from baseline in PRO scores to assess the burden of hypoglycemia",
                    "timeFrame": "26 and 52 weeks"
                },
                {
                    "measure": "11-item/Short Form Hypoglycemia Fear Scale",
                    "description": "Change from baseline in PRO scores to assess the burden of hypoglycemia",
                    "timeFrame": "26 and 52 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Individuals \u226518 years\n* Diagnosed T1DM with a minimum of 5 years since diagnosis\n* Has had at least 1 hypoglycemic event of Level 2 (glucose level \\<54 mg/dL or \\<3 mmol/L, \\[CGM or SMBG confirmed\\]) or Level 3 (defined as a severe hypoglycemia with altered mental state and/or physical status requiring assistance) in the last 2 months prior to Screening\n* HbA1c value of \\<9.5% at Screening\n* Is currently on CSII (closed-loop systems are prohibited) or is on MDI for at least 6 months prior to the Screening Visit and is willing to stay on same type of insulin treatment and the current mode of insulin administration (CSII or MDI injection treatments) for the duration of the study\n* Must have used a CGM device for at least 3 consecutive months prior to Screening\n\nExclusion Criteria:\n\n* Has T2DM, monogenic diabetes, maturity-onset diabetes of the young, other unusual or rare forms of diabetes mellitus, or diabetes resulting from a secondary disease\n* Has been hospitalized for DKA within 3 months prior to Screening\n* Has uncontrolled hypothyroidism or hyperthyroidism\n* History of eating disorder within the last 2 years such as anorexia, bulimia, diabulimia or neglecting to give insulin to manipulate weight\n* Has an active or untreated malignancy, or has been in remission from malignancy for \u22645 years except well-treated basal cell or squamous cell skin cancer or cervical cancer in situ\n* Has used any of the following medications within the specified time periods - any non- insulin anti-diabetic therapies, e.g., sodium glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, metformin, sulfonylureas, dipeptidyl peptidase 4 (DPP-4) inhibitors, or pramlintide within 90 days prior to the Screening or weight loss medications within 30 days prior to the Screening\n* Has used a hybrid closed-loop system (e.g., Medtronic 670G, Omnipod 5, or Tandem X2 with control IQ) or Do-It-Yourself looping within the last 1 month prior to the Screening Visit, and agrees to not start hybrid closed-loop systems or Do-It-Yourself looping during the study.\n* Has an estimated glomerular filtration rate (eGFR) \\<30 mL/min/1.73 m2 utilizing the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at Screening\n* Has persistent, uncontrolled hypertension prior to Screening",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jennifer Freeman, Ph.D.",
                    "role": "CONTACT",
                    "phone": "(336) 888-0435",
                    "email": "clinicaltrials@vtvtherapeutics.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Thomas Strack, MD",
                    "affiliation": "vTv Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Advanced Metabolic Care & Research Institute, Inc. (AMCR)",
                    "status": "RECRUITING",
                    "city": "Escondido",
                    "state": "California",
                    "zip": "92025",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.11921,
                        "lon": -117.08642
                    }
                },
                {
                    "facility": "Denver Endocrinology Diabetes and Thyroid Center",
                    "status": "RECRUITING",
                    "city": "Englewood",
                    "state": "Colorado",
                    "zip": "80113",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 39.64777,
                        "lon": -104.98776
                    }
                },
                {
                    "facility": "ALL Medical Research, LLC",
                    "status": "RECRUITING",
                    "city": "Cooper City",
                    "state": "Florida",
                    "zip": "33024",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.05731,
                        "lon": -80.27172
                    }
                },
                {
                    "facility": "Metabolic Research Institute, Inc",
                    "status": "RECRUITING",
                    "city": "West Palm Beach",
                    "state": "Florida",
                    "zip": "33413",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 26.71534,
                        "lon": -80.05337
                    }
                },
                {
                    "facility": "Atlanta Diabetes Associates",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30318",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "Centricity Research - Columbus",
                    "status": "RECRUITING",
                    "city": "Columbus",
                    "state": "Georgia",
                    "zip": "31904",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.46098,
                        "lon": -84.98771
                    }
                },
                {
                    "facility": "Endocrine Research Solutions, Inc",
                    "status": "RECRUITING",
                    "city": "Roswell",
                    "state": "Georgia",
                    "zip": "30076",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.02316,
                        "lon": -84.36159
                    }
                },
                {
                    "facility": "Iowa Diabetes Research",
                    "status": "RECRUITING",
                    "city": "West Des Moines",
                    "state": "Iowa",
                    "zip": "50265",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.57721,
                        "lon": -93.71133
                    }
                },
                {
                    "facility": "Asheville Clinical Research",
                    "status": "RECRUITING",
                    "city": "Asheville",
                    "state": "North Carolina",
                    "zip": "28803",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.60095,
                        "lon": -82.55402
                    }
                },
                {
                    "facility": "University of North Carolina at Chapel Hill",
                    "status": "RECRUITING",
                    "city": "Chapel Hill",
                    "state": "North Carolina",
                    "zip": "27514",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.9132,
                        "lon": -79.05584
                    }
                },
                {
                    "facility": "Lucas Research, Inc",
                    "status": "RECRUITING",
                    "city": "Morehead City",
                    "state": "North Carolina",
                    "zip": "28557",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.72294,
                        "lon": -76.72604
                    }
                },
                {
                    "facility": "Velocity Clinical Research - Medford",
                    "status": "RECRUITING",
                    "city": "Medford",
                    "state": "Oregon",
                    "zip": "97504",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.32652,
                        "lon": -122.87559
                    }
                },
                {
                    "facility": "Texas Diabetes and Endocrinology, P.A",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78731",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "Velocity Clinical Research - Dallas",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75230",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                },
                {
                    "facility": "Consano Clinical Research",
                    "status": "RECRUITING",
                    "city": "Shavano Park",
                    "state": "Texas",
                    "zip": "78231",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.58495,
                        "lon": -98.55252
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003922",
                    "term": "Diabetes Mellitus, Type 1"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M7117",
                    "name": "Diabetes Mellitus, Type 1",
                    "asFound": "Diabetes Mellitus, Type 1",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}